Novavax Begins Early Stage Clinical Study of Its Coronavirus Vaccine Candidate

Novavax (NASDAQ: NVAX) announced on Monday that it had begun enrolling participants in a phase 1/2 clinical trial of its coronavirus vaccine candidate NVX-CoV2373. The vaccine candidate demonstrated promising results in preclinical testing, including a significant immune system response and high levels of neutralizing antibodies, which bind to the novel coronavirus and block infection. The clinical study will consist of two parts.